- Home
- SOGP vs RLMD Comparison
SOGP vs RLMD Comparison
Compare SOGP & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOGP
- RLMD
- Stock Information
- Founded
- SOGP 2010
- RLMD 2004
- Country
- SOGP Singapore
- RLMD United States
- Employees
- SOGP N/A
- RLMD N/A
- Industry
- SOGP
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- SOGP
- RLMD Health Care
- Exchange
- SOGP NYSE
- RLMD Nasdaq
- Market Cap
- SOGP 9.8M
- RLMD 11.5M
- IPO Year
- SOGP 2020
- RLMD N/A
- Fundamental
- Price
- SOGP $2.20
- RLMD $0.74
- Analyst Decision
- SOGP
- RLMD Hold
- Analyst Count
- SOGP 0
- RLMD 4
- Target Price
- SOGP N/A
- RLMD $4.25
- AVG Volume (30 Days)
- SOGP 42.0K
- RLMD 3.0M
- Earning Date
- SOGP 05-15-2025
- RLMD 05-07-2025
- Dividend Yield
- SOGP N/A
- RLMD N/A
- EPS Growth
- SOGP N/A
- RLMD N/A
- EPS
- SOGP N/A
- RLMD N/A
- Revenue
- SOGP $243,832,033.00
- RLMD N/A
- Revenue This Year
- SOGP $40.56
- RLMD N/A
- Revenue Next Year
- SOGP $3.88
- RLMD N/A
- P/E Ratio
- SOGP N/A
- RLMD N/A
- Revenue Growth
- SOGP N/A
- RLMD N/A
- 52 Week Low
- SOGP $1.49
- RLMD $0.24
- 52 Week High
- SOGP $3.36
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- SOGP 54.33
- RLMD 88.76
- Support Level
- SOGP $2.00
- RLMD $0.27
- Resistance Level
- SOGP $2.29
- RLMD $0.33
- Average True Range (ATR)
- SOGP 0.16
- RLMD 0.07
- MACD
- SOGP 0.02
- RLMD 0.05
- Stochastic Oscillator
- SOGP 86.61
- RLMD 96.79
About SOGP SOUND GROUP INC SPON ADS EA REP 200 ORD SHS(POST SPLIT)
Sound Group Inc is a world-wide audio-centric social and entertainment company. It Leverages broad product portfolio and in-house technologies, Sound Group caters to user interest in audio entertainment and social networking. Sound Group nurtures a globally diverse and inclusive team, drawing on talent from various countries and regions world-wide.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.